• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    CeriBell Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/8/25 4:13:36 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $CBLL alert in real time by email
    8-K
    0001861107false00018611072025-05-082025-05-08

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 8, 2025

    CeriBell, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

     

     

    Delaware

    001-281784

    47-1785452

    (State or other jurisdiction

    of incorporation)

    (Commission

    File Number)

    (IRS Employer

    Identification Number)

     

     

     

     

     

    360 N. Pastoria Avenue

    Sunnyvale, California

     

     

     

     

    94085

    (Address of principal executive offices)

     

     

     

    (Zip Code)

    Registrant’s telephone number, including area code: (800) 436-0826

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     


     

     

     

     

     

     

    Title of each class

    Trading Symbol(s)

    Name of each exchange on which registered

    Common Stock, $0.001 par value per share

    CBLL

    The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

     

    Emerging growth company

    ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


     

    Item 2.02

    Results of Operations and Financial Condition.

    On May 8, 2025, Ceribell, Inc. issued a press release announcing its financial results for the fiscal quarter ended March 31, 2025. A copy of the press release, dated May 8, 2025, is furnished hereto as Exhibit 99.1 and is incorporated herein by reference.

    The foregoing information in this Item 2.02 (including the exhibit hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

     

    Item 9.01

    Financial Statements and Exhibits.

     

    Exhibit No.

    Description

    99.1

    Press Release of CeriBell, Inc., dated May 8, 2025

    104

    Cover Page Interactive Data File, formatted in Inline XBRL.

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

     

     

     

     

     

     

    CERIBELL, INC.

     

     

     

     

    Date: May 8, 2025

     

    By:

    /s/ Scott Blumberg

     

     

     

    Scott Blumberg

     

     

     

    Chief Financial Officer

     

     


    Get the next $CBLL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CBLL

    DatePrice TargetRatingAnalyst
    4/4/2025$32.00Buy
    Ladenburg Thalmann
    11/5/2024$32.00Buy
    BofA Securities
    11/5/2024$30.00Buy
    Canaccord Genuity
    11/5/2024$32.00Overweight
    JP Morgan
    11/5/2024$31.00Buy
    TD Cowen
    11/5/2024Outperform
    William Blair
    More analyst ratings

    $CBLL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ceribell to Participate in the William Blair 45th Annual Growth Stock Conference

      SUNNYVALE, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming William Blair 45th Annual Growth Stock Conference. The presentation will take place on Tuesday, June 3, 2025, at 7:20 a.m. Pacific Standard Time / 9:20 a.m. Central Standard Time.  Event: William Blair 45th Annual Growth Stock ConferenceDate: Tuesday, June 3, 2025Time: 7:20 a.m. PST / 9:20 a.m. CST A live and archived webcast of the presentation will be available in the "Inv

      5/20/25 4:05:00 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Ceribell Reports First Quarter 2025 Financial Results

      SUNNYVALE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended March 31, 2025. First Quarter 2025 & Recent Highlights Reported total revenue of $20.5 million in the first quarter of 2025, a 42% increase compared to the same period in 2024Ended the quarter with 558 total active accounts Achieved gross margin of 88% in the first quarter of 2025Received U.S. Food and Drug Administration 510(k) clearance for expansion of Clarity™ algorithm indication, becoming the first s

      5/8/25 4:05:00 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Ceribell to Participate in the Bank of America Securities 2025 Health Care Conference

      SUNNYVALE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming Bank of America Securities 2025 Health Care Conference. The presentation will take place on Wednesday, May 14, 2025, at 10:55 a.m. Pacific Standard Time / 1:55 p.m. Eastern Standard Time.  Event: Bank of America Securities 2025 Health Care ConferenceDate: Wednesday, May 14, 2025Time: 10:55 a.m. PST / 1:55p.m. EST A live and archived webcast of the presentation will be availabl

      4/30/25 4:05:00 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CBLL
    Leadership Updates

    Live Leadership Updates

    See more
    • Ceribell Appoints Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing

      —Ms. Rodenbush to lead hiring and talent development initiatives— —Mr. Price to focus on market development and penetration— SUNNYVALE, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions ("Ceribell"), today announced the appointments of Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing to its leadership team. "Ms. Rodenbush and Mr. Price bring an impressive wealth of experience to Ceribell, and I am confident that their leadership across our People & Culture and Marketing fu

      11/19/24 8:00:00 AM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CBLL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Chao Xingjuan exercised 73,871 shares at a strike of $1.02 and sold $424,000 worth of shares (25,000 units at $16.96), increasing direct ownership by 7% to 776,022 units (SEC Form 4)

      4 - Ceribell, Inc. (0001861107) (Issuer)

      5/19/25 12:33:00 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • President and CEO Chao Xingjuan sold $240,657 worth of shares (15,928 units at $15.11), decreasing direct ownership by 2% to 727,151 units (SEC Form 4)

      4 - Ceribell, Inc. (0001861107) (Issuer)

      4/24/25 4:47:39 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • President and CEO Chao Xingjuan sold $136,295 worth of shares (9,072 units at $15.02), decreasing direct ownership by 1% to 743,079 units (SEC Form 4)

      4 - Ceribell, Inc. (0001861107) (Issuer)

      4/21/25 9:31:10 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CBLL
    Financials

    Live finance-specific insights

    See more
    • Ceribell Reports First Quarter 2025 Financial Results

      SUNNYVALE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended March 31, 2025. First Quarter 2025 & Recent Highlights Reported total revenue of $20.5 million in the first quarter of 2025, a 42% increase compared to the same period in 2024Ended the quarter with 558 total active accounts Achieved gross margin of 88% in the first quarter of 2025Received U.S. Food and Drug Administration 510(k) clearance for expansion of Clarity™ algorithm indication, becoming the first s

      5/8/25 4:05:00 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Ceribell to Report First Quarter 2025 Financial Results on May 8, 2025

      SUNNYVALE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the first quarter of 2025 after the close of trading on Thursday, May 8, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on May 8, 2025. Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 7370458. A li

      4/24/25 4:05:00 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Ceribell to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

      SUNNYVALE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the fourth quarter and full year of 2024 after the close of trading on Tuesday, February 25, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on February 25, 2025. Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing

      2/11/25 4:05:00 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CBLL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ladenburg Thalmann initiated coverage on CeriBell with a new price target

      Ladenburg Thalmann initiated coverage of CeriBell with a rating of Buy and set a new price target of $32.00

      4/4/25 8:27:23 AM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BofA Securities initiated coverage on CeriBell with a new price target

      BofA Securities initiated coverage of CeriBell with a rating of Buy and set a new price target of $32.00

      11/5/24 7:25:17 AM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Canaccord Genuity initiated coverage on CeriBell with a new price target

      Canaccord Genuity initiated coverage of CeriBell with a rating of Buy and set a new price target of $30.00

      11/5/24 6:16:50 AM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CBLL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Tpg Gp A, Llc converted options into 3,587,154 shares and bought $6,464,556 worth of shares (380,268 units at $17.00) (SEC Form 4)

      4 - Ceribell, Inc. (0001861107) (Issuer)

      10/17/24 4:14:38 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Tammenoms Bakker Juliet was granted 6,618 shares, converted options into 2,140,600 shares and bought $4,032,978 worth of shares (237,234 units at $17.00) (SEC Form 4)

      4 - Ceribell, Inc. (0001861107) (Issuer)

      10/16/24 4:18:06 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CBLL
    SEC Filings

    See more

    $CBLL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form 144 filed by CeriBell Inc.

      144 - Ceribell, Inc. (0001861107) (Subject)

      5/15/25 10:47:33 AM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 10-Q filed by CeriBell Inc.

      10-Q - Ceribell, Inc. (0001861107) (Filer)

      5/8/25 4:36:43 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CeriBell Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Ceribell, Inc. (0001861107) (Filer)

      5/8/25 4:13:36 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by CeriBell Inc.

      SC 13G - Ceribell, Inc. (0001861107) (Subject)

      11/7/24 9:24:55 AM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13D filed by CeriBell Inc.

      SC 13D - Ceribell, Inc. (0001861107) (Subject)

      10/22/24 4:20:26 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care